Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 3
1986 1
1987 2
1995 1
1996 2
1998 6
1999 6
2000 7
2001 9
2002 14
2003 8
2004 21
2005 32
2006 32
2007 23
2008 19
2009 30
2010 43
2011 46
2012 33
2013 44
2014 38
2015 41
2016 48
2017 30
2018 33
2019 26
2020 29
2021 25
2022 29
2023 23
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

638 results

Results by year

Filters applied: . Clear all
Page 1
Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R. Cacabelos R. Int J Mol Sci. 2017 Mar 4;18(3):551. doi: 10.3390/ijms18030551. Int J Mol Sci. 2017. PMID: 28273839 Free PMC article. Review.
As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. ...Since biochemical changes and therapeutic outcomes are highly dependent upon the genomic profiles of PD patients, personalized treatments should rely on pharm …
As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. ...Since biochemical changes …
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee. Fox SH, et al. Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, n …
There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine ago …
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
Tan YY, Jenner P, Chen SD. Tan YY, et al. J Parkinsons Dis. 2022;12(2):477-493. doi: 10.3233/JPD-212976. J Parkinsons Dis. 2022. PMID: 34957948 Free PMC article. Review.
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have …
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor m …
Rasagiline.
Siddiqui MA, Plosker GL. Siddiqui MA, et al. Drugs Aging. 2005;22(1):83-91; discussion 93-4. doi: 10.2165/00002512-200522010-00006. Drugs Aging. 2005. PMID: 15663351 Review.
Rasagiline also possesses neuroprotective properties that are independent of its MAO inhibitory activity. ...Rasagiline has shown significant beneficial effects as monotherapy in the treatment of early Parkinson's disease. ...
Rasagiline also possesses neuroprotective properties that are independent of its MAO inhibitory activity. ...Rasagiline has sh
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R, Cai H, Cui Y, Su D, Cai G, Lin F, Feng T. Yan R, et al. Eur J Neurol. 2023 Apr;30(4):1118-1134. doi: 10.1111/ene.15651. Epub 2022 Dec 11. Eur J Neurol. 2023. PMID: 36437702 Review.
The present study aimed to compare the efficacy and safety of MAO-BIs plus and conventional MAO-BIs, as well as their corresponding doses, as adjuvant therapy to levodopa in the treatment of Parkinson's disease (PD). METHOD: Randomized controlled trials enrolling PD
The present study aimed to compare the efficacy and safety of MAO-BIs plus and conventional MAO-BIs, as well as their corresponding doses, a …
Rasagiline in Parkinson's disease.
Chahine LM, Stern MB. Chahine LM, et al. Int Rev Neurobiol. 2011;100:151-68. doi: 10.1016/B978-0-12-386467-3.00008-X. Int Rev Neurobiol. 2011. PMID: 21971007 Review.
Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. ...Given the demonstrated benefits of rasagiline, along with its safety and tolerability profile, it has an important role to play in PD th
Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. ...Given the
Rasagiline Withdrawal Syndrome in Parkinson's Disease.
Solla P, Ercoli T, Masala C, Orofino G, Fadda L, Corda DG, Zarbo IR, Meloni M, Sechi E, Bagella CF, Defazio G. Solla P, et al. Brain Sci. 2022 Feb 5;12(2):219. doi: 10.3390/brainsci12020219. Brain Sci. 2022. PMID: 35203982 Free PMC article.
To date, no DRT-related withdrawal syndrome has been described in PD patients who discontinue rasagiline, an irreversible inhibitor of monoamine oxidase-B (MAO-B). Here we report three PD patients who developed a severe withdrawal syndrome after rasagiline
To date, no DRT-related withdrawal syndrome has been described in PD patients who discontinue rasagiline, an irreversible inhi …
Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
Chang Y, Wang LB, Li D, Lei K, Liu SY. Chang Y, et al. Ann Med. 2017 Aug;49(5):421-434. doi: 10.1080/07853890.2017.1293285. Epub 2017 Mar 15. Ann Med. 2017. PMID: 28293967 Review.
The aim of the study was to analyze the effectiveness of rasagiline in treatment of Parkinson's disease (PD), both as monotherapy and combination therapy. ...CONCLUSIONS: Our results confirm the efficacy of rasagiline in PD. Further studies are require …
The aim of the study was to analyze the effectiveness of rasagiline in treatment of Parkinson's disease (PD), both as monother …
Rasagiline.
Schapira A, Bate G, Kirkpatrick P. Schapira A, et al. Nat Rev Drug Discov. 2005 Aug;4(8):625-6. doi: 10.1038/nrd1803. Nat Rev Drug Discov. 2005. PMID: 16106586 No abstract available.
The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J, Bortan E. Leegwater-Kim J, et al. Clin Interv Aging. 2010 May 25;5:149-56. doi: 10.2147/cia.s4145. Clin Interv Aging. 2010. PMID: 20517484 Free PMC article. Review.
Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. ...In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early
Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of
638 results